Nervous Disorder TRIZ Cases

This case examines Formula (I) compounds that target LRRK2 kinase activity beyond symptom management for Parkinson's disease.

Specific heterocyclic rings and substituents tune orexin 2 receptor activity while addressing safety and pharmacokinetic limits.

Curcumin-derived chalcone analogues target Aβ aggregation, addressing blood-brain barrier delivery and temporary plaque clearance.

This case uses smartphone or web-based CBT to treat perinatal mood disorders, alone or alongside pharmacotherapy.

This case develops nitrogen-containing heteroaryl compounds that selectively modulate PINK1, enhance mitophagy, and limit toxicity.

This case uses a sequence-defined peptide to reduce tau oligomers and hyperphosphorylation, improving motor and cognitive function.

A localized biodegradable lipid structure supports efficient gene silencing and nucleic acid delivery with reduced liver toxicity.

This case combines lutein, zeaxanthin, meso-zeaxanthin, and fish oil to stabilize cognition during Alzheimer's disease progression.

This case uses a 3-fluorobenzenepropanoate ester to reduce gastrointestinal irritation while supporting oral and parenteral dosing.

This case uses characterized dental pulp stem cells and multiple doses to promote neurogenesis and improve motor and memory functions.

Human platelet lysate replaces FBS to produce characterized dental pulp stem cells with tissue-regeneration potential.

Tailored spacers and molecular substitutions create cGMP multimers for broader PKG activation with improved target selectivity.

This case uses aqueous HCl crystallization and acetonitrile/water slurrying to produce a stable, purer APC hydrochloride solvate.

This case uses a p25-targeting peptide to reduce pathological CDK5 activity, protect neurons, and limit disruption of normal function.

Stalk-epitope antibodies selectively activate membrane-bound TREM2, reduce soluble TREM2, and promote Aβ plaque compaction.

This case uses antibodies against ApoE HSPG-binding sites to limit harmful interactions linked to cognitive decline and neurodegeneration.

This case combines a GLP-1 agonist, peptide linker, and clearance-reducing moiety to extend half-life and reduce dosing frequency.

Purified 6-OH CBD targets inconsistent cannabinoid preparations for anticonvulsant use.

Glucuronide, unsaturated glycosyl, ester, and ether prodrugs convert in vivo to support oral exposure and steadier dopaminergic treatment.

This case shows how POZ polymer characteristics and degradable linkages tune drug release, half-life, and local effects.

Mannose-fused antigens bind mannose receptors on antigen-presenting cells, inducing tolerance and limiting anti-drug immune responses.

Transition-metal complexes with pyranone or pyridone ligands pursue analgesia with fewer GI side effects.

Medin-binding nanoliposomes reduce vascular toxicity, inflammation, and oxidative stress.

An oral CX-8998 formulation combines immediate and controlled release to sustain plasma levels for 12-24 hours.

This case pairs anti-CGRP antibody dosing with MBS and PGIC measures for broader migraine relief beyond headache reduction.

Defined ratios of purified serotonergic drugs aim to improve receptor consistency, speed mood effects, and reduce adverse psychedelic experiences.

This case uses NRF1-targeted antisense oligonucleotides to inhibit FBXO46 activity and address Alzheimer’s disease mechanisms.

This case uses blood marker monitoring and dose adjustment to manage tacrolimus toxicity when purified CBD treats childhood-onset epilepsy.

Combining RXR agonists with thyroid hormones targets remyelination and neuroprotection.

Selective anti-sIL7R antibodies target autoimmune signaling while preserving membrane IL7R function.

Three crystalline ITI-007 hydrochloride polymorphs address poor solubility, stickiness, hygroscopicity, and salt instability.

Flexible panels secure an inhaler in a compact wallet, reducing carry bulk and preparation time during urgent medication use.

This case uses X-ray-defined Form 3 and pharmaceutical excipients to improve composition stability and extend chronic pain relief.

A capture-and-detection antibody pair quantifies Aβ42 oligomers in human body fluids, addressing specificity and sensitivity limits.

This case pairs CX157 or another MAOI with DMT to limit metabolic clearance and support accessible oral treatment.

This case combines propylene carbonate with polyhydric alcohols to dissolve at least 5% apomorphine for continuous transdermal delivery.

This case uses compound (I) to break down accumulated GM1 ganglioside, supporting neuronal survival without brain-cell toxicity.

This case uses segmented R1 and R2 substituents to tune orexin receptor activity across sleep and metabolic disorders.

Selected genes delivered by AAV address alpha-synuclein, mitochondrial, and lysosomal dysfunction in Parkinson's disease.

Bupropion inhibits dextromethorphan metabolism for longer plasma exposure and fewer doses.

Viscous nasal cannabinoid compositions bypass first-pass metabolism for rapid delivery.

Novel hydroxamic acid derivatives address weak meprin inhibitors with selective dual activity for meprin α and β.

This case uses segmented reactions and amino-group substitution to modify psilocybin for psychiatric treatment with fewer adverse effects.

This case uses a 7–32 amino acid peptide solution that forms a hydrogel for easier anti-adhesion application at surgical and bleeding sites.

Mesylate salt improves para-topolin solubility for cosmetic and therapeutic use.

This case uses maternal anti-HSV antibodies to prevent neonatal transmission and reduce mortality and neurological pathology.

This case uses a compact FMR1 promoter, isoform 7, and 3′ regulatory element in AAV9 to restore FMRP expression.

Carbodiimides and related coupling agents in organic solvents streamline amide-bond formation for efficient synthesis.

This formulation pairs PYY(3-36) with a DPP-IV inhibitor to improve satiety and glycemic control while limiting systemic side effects.

Tyrosine and resveratrol derivatives selectively tune TyrRS to separate DNA repair from protein-synthesis effects and reduce high-dose harm.